FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and
Category: Financial Results
Ipsen Delivers Strong Growth and Expands Oncology Pipeline
We are proud to announce our robust performance across all therapeutic areas in the first nine months of 2025, underscoring
Ipsen’s financial results for the first nine months of 2025
H1 Results: a strong first half of 2025
The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our
H1 2025 Results
Q1 2025 sales update
2024: A year of achievements and progress
Our performance in 2024 confirmed that our strategic initiatives are paying off, with significant advancements and robust financial growth across
Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
The first six months of 2024 saw excellent sales growth of 9.5% at CER, and a core operating margin of
Ipsen delivers FY 2023 results and anticipates four launches in 2024
Hear what Ipsen CEO David Loew has to say about our solid full-year results and a new era of dynamic
2023 year to date and third-quarter sales results
Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET. Press release